<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34962225</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Novel cannula design improves large volume auto-injection rates for high viscosity solutions.</ArticleTitle>
        <Pagination>
          <StartPage>43</StartPage>
          <EndPage>51</EndPage>
          <MedlinePgn>43-51</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2021.2018069</ELocationID>
        <Abstract>
          <AbstractText>A prototype reusable large-volume (2 mL) autoinjector (LVAI) was designed to compare injection performance of a novel 27 gauge ultra-thin wall (UTW) pre-filled syringe (PFS) cannula (8 mm external cannula length, 14.4 mm total needle length) against an existing 27 gauge special thin wall (STW) PFS cannula (12.7 mm external cannula length, 19 mm total needle length) across a range of injectate viscosities (2.3-30 cP) in a series of <i>in vivo</i> feasibility studies in swine. The UTW cannula had an approximately 30% greater cross-sectional lumen area than the STW cannula. The target exposed needle length was adjusted to ensure appropriate needle penetration depth and achieve injectate deposition in the subcutaneous (SC) tissue. Delivery time and volume, injection site leakage, injectate depot location, and local tissue effects were examined. The STW and UTW cannulae both provided effective SC delivery of contrast placebo solutions, and were able to accommodate injectate viscosity up to 30 cP without quantifiable leakage from the tissue and with minor tissue effects which resolved within 1-2 hours. Delivery times at each viscosity were significantly different between PFS types with the UTW PFS producing faster delivery times. In a histological substudy of the UTW cannula using injectate viscosities up to 50 cP, injection site reactions were rare and, when present, were of minimal severity. This series of studies demonstrates the feasibility of LVAI SC injection and informs autoinjector and PFS design considerations. Use of a UTW cannula may enable more rapid LVAI injections with minimal tissue effects, especially for higher viscosity formulations.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Roberts</LastName>
            <ForeName>Bruce C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rini</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klug</LastName>
            <ForeName>Rick</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sherman</LastName>
            <ForeName>Douglas B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morel</LastName>
            <ForeName>Didier</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>BD Clinical Development, Pont-de-Claix, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pettis</LastName>
            <ForeName>Ronald J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072601" MajorTopicYN="Y">Cannula</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075662" MajorTopicYN="N">Injection Site Reaction</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014783" MajorTopicYN="Y">Viscosity</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Large volume subcutaneous injection</Keyword>
        <Keyword MajorTopicYN="N">autoinjector</Keyword>
        <Keyword MajorTopicYN="N">high viscosity</Keyword>
        <Keyword MajorTopicYN="N">injection depth</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
        <Keyword MajorTopicYN="N">pre-filled syringe</Keyword>
        <Keyword MajorTopicYN="N">tissue response</Keyword>
        <Keyword MajorTopicYN="N">ultra-thin wall cannula</Keyword>
      </KeywordList>
      <CoiStatement>Bruce Roberts, Christopher Rini, Rick Klug, Douglas B. Sherman, Didier Morel, and Ronald J. Pettis are employees and potential stockholders of BD, which sponsored this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34962225</ArticleId>
        <ArticleId IdType="pmc">PMC8725910</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2021.2018069</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al.  (2012). Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol
32:1180–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22730009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allmendinger A, Fischer S, Huwyler J, et al.  (2014). Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions. Eur J Pharm Biopharm
87:318–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24560966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allmendinger A, Mueller R, Schwarb E, et al.  (2015). Measuring tissue back-pressure—in vivo injection forces during subcutaneous injection. Pharm Res
32:2229–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25537343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein D, Pavord ID, Chapman KR, et al.  (2020). Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma
57:987–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31251090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berteau C, Filipe-Santos O, Wang T, et al.  (2015). Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices
8:473–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4646585</ArticleId>
            <ArticleId IdType="pubmed">26635489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bittner B, Richter W, Schmidt J. (2018). Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs
32:425–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6182494</ArticleId>
            <ArticleId IdType="pubmed">30043229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dias C, Abosaleem B, Crispino C, et al.  (2015). Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech
16:1101–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4674646</ArticleId>
            <ArticleId IdType="pubmed">25693652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doughty DV, Clawson CZ, Lambert W, Subramony JA. (2016). Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci
105:2105–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27287520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson GT, Cole J, Aurivillius M, et al.  (2019). Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J Asthma Allergy
12:363–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6815754</ArticleId>
            <ArticleId IdType="pubmed">31695439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias JP, Koren MJ, Loizeau V, et al.  (2020). The SYDNEY device study: a multicenter, randomized, open-label usability study of a 2-ml alirocumab autoinjector device. Clin Ther
42:94–107.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31879033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibney MA, Arce CH, Byron KJ, Hirsch LJ. (2010). Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin
26:1519–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20429833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch L, Byron K, Gibney M. (2014). Intramuscular risk at insulin injection sites – measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther
16:867–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25329935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu P, Wang J, Florian J, et al.  (2020). Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J
22:52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32107671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudry C, Lebrun A, Moura B, et al.  (2017). Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatol Ther
4:183–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5443726</ArticleId>
            <ArticleId IdType="pubmed">28243967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackisch C, Müller V, Dall P, et al.  (2015). Subcutaneous trastuzumab for HER2-positive breast cancer – evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd
75:566–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4490923</ArticleId>
            <ArticleId IdType="pubmed">26166837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones GB, Collins DS, Harrison MW, et al.  (2017). Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med
9:eaaf9166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28855399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang DW, Oh DA, Fu GY, et al.  (2013). Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. J Pharmacol Toxicol Methods
67:140–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23376811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laurent PE, Pettis R, Easterbrook W, Berube J. (2006). Evaluating new hypodermic and intradermal injection devices. Med Device Technol
17:16–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16610713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathaes R, Koulov A, Joerg S, Mahler H-C. (2016). Subcutaneous injection volume of biopharmaceuticals—pushing the boundaries. J Pharm Sci
105:2255–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27378678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>OECD . (2015). Guidelines for the testing of chemicals, section 4, test no. 404: acute dermal irritation/corrosion. Paris, France: OECD Publishing.</Citation>
        </Reference>
        <Reference>
          <Citation>Olofsson S, Norrlid H, Karlsson E, et al.  (2016). Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast
29:140–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27498127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini C, Roberts BC, Morel D, et al.  (2019). Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol
13:533–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6501541</ArticleId>
            <ArticleId IdType="pubmed">30880448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rule S, Collins G, Samanta K. (2014). Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ
17:459–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24720836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shapiro R. (2010). Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol
30:301–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20082124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shire SJ, Shahrokh Z, Liu J. (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci
93:1390–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15124199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swindle MM, Makin A, Herron AJ, Clubb
FJ, Jr, et al.  (2012). Swine as models in biomedical research and toxicology testing. Vet Pathol
49:344–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21441112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swindle M. (2015). Swine in the laboratory: surgery, anesthesia, imaging and experimental techniques. 3rd ed.
Boca Raton: CRC Press.</Citation>
        </Reference>
        <Reference>
          <Citation>Usach I, Martinez R, Festini T, Peris JE. (2019). Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther
36:2986–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6822791</ArticleId>
            <ArticleId IdType="pubmed">31587143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasserman RL, Melamed I, Kobrynski L, et al.  (2011). Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol
31:323–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21424824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watt RP, Khatri H, Dibble ARG. (2019). Injectability as a function of viscosity and dosing materials for subcutaneous administration. Int J Pharm
554:376–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30414478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright L, Barnes TJ, Prestidge CA. (2020). Oral delivery of protein-based therapeutics: gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int J Pharm
585:119488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32504774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao X, Li W, Clawson C, et al.  (2018). Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence
12:515–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5898887</ArticleId>
            <ArticleId IdType="pubmed">29674844</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34962225</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Novel cannula design improves large volume auto-injection rates for high viscosity solutions.</ArticleTitle>
        <Pagination>
          <StartPage>43</StartPage>
          <EndPage>51</EndPage>
          <MedlinePgn>43-51</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2021.2018069</ELocationID>
        <Abstract>
          <AbstractText>A prototype reusable large-volume (2 mL) autoinjector (LVAI) was designed to compare injection performance of a novel 27 gauge ultra-thin wall (UTW) pre-filled syringe (PFS) cannula (8 mm external cannula length, 14.4 mm total needle length) against an existing 27 gauge special thin wall (STW) PFS cannula (12.7 mm external cannula length, 19 mm total needle length) across a range of injectate viscosities (2.3-30 cP) in a series of <i>in vivo</i> feasibility studies in swine. The UTW cannula had an approximately 30% greater cross-sectional lumen area than the STW cannula. The target exposed needle length was adjusted to ensure appropriate needle penetration depth and achieve injectate deposition in the subcutaneous (SC) tissue. Delivery time and volume, injection site leakage, injectate depot location, and local tissue effects were examined. The STW and UTW cannulae both provided effective SC delivery of contrast placebo solutions, and were able to accommodate injectate viscosity up to 30 cP without quantifiable leakage from the tissue and with minor tissue effects which resolved within 1-2 hours. Delivery times at each viscosity were significantly different between PFS types with the UTW PFS producing faster delivery times. In a histological substudy of the UTW cannula using injectate viscosities up to 50 cP, injection site reactions were rare and, when present, were of minimal severity. This series of studies demonstrates the feasibility of LVAI SC injection and informs autoinjector and PFS design considerations. Use of a UTW cannula may enable more rapid LVAI injections with minimal tissue effects, especially for higher viscosity formulations.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Roberts</LastName>
            <ForeName>Bruce C</ForeName>
            <Initials>BC</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rini</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klug</LastName>
            <ForeName>Rick</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sherman</LastName>
            <ForeName>Douglas B</ForeName>
            <Initials>DB</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morel</LastName>
            <ForeName>Didier</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>BD Clinical Development, Pont-de-Claix, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pettis</LastName>
            <ForeName>Ronald J</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Translational and Clinical Sciences Center of Excellence, BD Technologies and Innovation, Research Triangle Park, NC, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072601" MajorTopicYN="Y">Cannula</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000075662" MajorTopicYN="N">Injection Site Reaction</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
          <QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014783" MajorTopicYN="Y">Viscosity</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Large volume subcutaneous injection</Keyword>
        <Keyword MajorTopicYN="N">autoinjector</Keyword>
        <Keyword MajorTopicYN="N">high viscosity</Keyword>
        <Keyword MajorTopicYN="N">injection depth</Keyword>
        <Keyword MajorTopicYN="N">in vivo</Keyword>
        <Keyword MajorTopicYN="N">pre-filled syringe</Keyword>
        <Keyword MajorTopicYN="N">tissue response</Keyword>
        <Keyword MajorTopicYN="N">ultra-thin wall cannula</Keyword>
      </KeywordList>
      <CoiStatement>Bruce Roberts, Christopher Rini, Rick Klug, Douglas B. Sherman, Didier Morel, and Ronald J. Pettis are employees and potential stockholders of BD, which sponsored this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>8</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34962225</ArticleId>
        <ArticleId IdType="pmc">PMC8725910</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2021.2018069</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al.  (2012). Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol
32:1180–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22730009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allmendinger A, Fischer S, Huwyler J, et al.  (2014). Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions. Eur J Pharm Biopharm
87:318–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24560966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allmendinger A, Mueller R, Schwarb E, et al.  (2015). Measuring tissue back-pressure—in vivo injection forces during subcutaneous injection. Pharm Res
32:2229–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25537343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein D, Pavord ID, Chapman KR, et al.  (2020). Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma
57:987–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31251090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berteau C, Filipe-Santos O, Wang T, et al.  (2015). Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance. Med Devices
8:473–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4646585</ArticleId>
            <ArticleId IdType="pubmed">26635489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bittner B, Richter W, Schmidt J. (2018). Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs
32:425–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6182494</ArticleId>
            <ArticleId IdType="pubmed">30043229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dias C, Abosaleem B, Crispino C, et al.  (2015). Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects. AAPS PharmSciTech
16:1101–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4674646</ArticleId>
            <ArticleId IdType="pubmed">25693652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doughty DV, Clawson CZ, Lambert W, Subramony JA. (2016). Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery. J Pharm Sci
105:2105–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27287520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferguson GT, Cole J, Aurivillius M, et al.  (2019). Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J Asthma Allergy
12:363–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6815754</ArticleId>
            <ArticleId IdType="pubmed">31695439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias JP, Koren MJ, Loizeau V, et al.  (2020). The SYDNEY device study: a multicenter, randomized, open-label usability study of a 2-ml alirocumab autoinjector device. Clin Ther
42:94–107.e5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31879033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibney MA, Arce CH, Byron KJ, Hirsch LJ. (2010). Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin
26:1519–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20429833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirsch L, Byron K, Gibney M. (2014). Intramuscular risk at insulin injection sites – measurement of the distance from skin to muscle and rationale for shorter-length needles for subcutaneous insulin therapy. Diabetes Technol Ther
16:867–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25329935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu P, Wang J, Florian J, et al.  (2020). Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J
22:52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32107671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudry C, Lebrun A, Moura B, et al.  (2017). Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. Rheumatol Ther
4:183–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5443726</ArticleId>
            <ArticleId IdType="pubmed">28243967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackisch C, Müller V, Dall P, et al.  (2015). Subcutaneous trastuzumab for HER2-positive breast cancer – evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd
75:566–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4490923</ArticleId>
            <ArticleId IdType="pubmed">26166837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones GB, Collins DS, Harrison MW, et al.  (2017). Subcutaneous drug delivery: an evolving enterprise. Sci Transl Med
9:eaaf9166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28855399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang DW, Oh DA, Fu GY, et al.  (2013). Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. J Pharmacol Toxicol Methods
67:140–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23376811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laurent PE, Pettis R, Easterbrook W, Berube J. (2006). Evaluating new hypodermic and intradermal injection devices. Med Device Technol
17:16–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16610713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathaes R, Koulov A, Joerg S, Mahler H-C. (2016). Subcutaneous injection volume of biopharmaceuticals—pushing the boundaries. J Pharm Sci
105:2255–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27378678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>OECD . (2015). Guidelines for the testing of chemicals, section 4, test no. 404: acute dermal irritation/corrosion. Paris, France: OECD Publishing.</Citation>
        </Reference>
        <Reference>
          <Citation>Olofsson S, Norrlid H, Karlsson E, et al.  (2016). Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast
29:140–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27498127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini C, Roberts BC, Morel D, et al.  (2019). Evaluating the impact of human factors and pen needle design on insulin pen injection. J Diabetes Sci Technol
13:533–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6501541</ArticleId>
            <ArticleId IdType="pubmed">30880448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rule S, Collins G, Samanta K. (2014). Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ
17:459–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24720836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shapiro R. (2010). Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol
30:301–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20082124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shire SJ, Shahrokh Z, Liu J. (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci
93:1390–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15124199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swindle MM, Makin A, Herron AJ, Clubb
FJ, Jr, et al.  (2012). Swine as models in biomedical research and toxicology testing. Vet Pathol
49:344–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21441112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swindle M. (2015). Swine in the laboratory: surgery, anesthesia, imaging and experimental techniques. 3rd ed.
Boca Raton: CRC Press.</Citation>
        </Reference>
        <Reference>
          <Citation>Usach I, Martinez R, Festini T, Peris JE. (2019). Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther
36:2986–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6822791</ArticleId>
            <ArticleId IdType="pubmed">31587143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasserman RL, Melamed I, Kobrynski L, et al.  (2011). Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol
31:323–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21424824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watt RP, Khatri H, Dibble ARG. (2019). Injectability as a function of viscosity and dosing materials for subcutaneous administration. Int J Pharm
554:376–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30414478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright L, Barnes TJ, Prestidge CA. (2020). Oral delivery of protein-based therapeutics: gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int J Pharm
585:119488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32504774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao X, Li W, Clawson C, et al.  (2018). Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system. Patient Prefer Adherence
12:515–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5898887</ArticleId>
            <ArticleId IdType="pubmed">29674844</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
